News Quantified

IONS – ionis pharmaceuticals, inc. (US:NASDAQ)

Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.

4/21

07:00 am

ions

Low

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis Pharmaceuticals (IONS) was given a new $110.00 price target by Canaccord Genuity Group Inc..

How The Ionis Pharmaceuticals (IONS) Story Is Shifting With New Targets And 2026 Catalysts [Yahoo! Finance]

Ionis to hold first quarter 2026 financial results webcast

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}